GP6 and ischemic stroke: Such achievement is of utmost importance considering that we also inform here on how a pharmacologic blockade of GPVI with glenzocimab (Acticor Biotech), an anti-GPVI F(ab) fragment evaluated in phase I clinical trials to prevent ischemic stroke, efficiently reduces experimental metastasis.